Matrix Metalloproteinase 3 Polymorphism

Gad, Sophie; Zinzindohoué, Franck; Manière, Isabelle; Beauregard, Janie; Trégouët, David‐Alexandre; Brasnu, Daniel; Beaune, Philippe; Laccourreye, O.; Laurent‐Puig, Pierre

doi:10.1158/1078-0432.ccr-1116-03

Cited by 33 publications

(28 citation statements)

References 27 publications

(25 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, they are in accordance with a publication by BLONS et al [6] which suggests modulation of chemotherapy response by altered MMP3 expression. The reason for this could be enhanced Fas ligand cleavage from the cell surface by MMP7 and MMP3 [25], leading to inhibition of the extrinsic apoptotic pathway.…”

Section: Discussionsupporting

confidence: 92%

See 1 more Smart Citation

Single nucleotide polymorphisms in matrix metalloproteinase genes and lung cancer chemotherapy response and prognosis

Scherf

Dally²,

Müller³

et al. 2009

European Respiratory Journal

View full text Add to dashboard Cite

The prognosis for lung cancer patients treated with chemotherapy is poor. Single nucleotide polymorphisms (SNPs) in matrix metalloproteinase (MMP) genes could influence treatment outcome by altering apoptotic pathways. Eight SNPs with known or suspected phenotypic effect in six genes (MMP1, MMP2, MMP3, MMP7, MMP9 and MMP12) were investigated.For 349 Caucasian patients with primary lung cancer, receiving first-line chemotherapy, three different endpoints were analysed: response after the second cycle, progression free survival (PFS) and overall survival (OS).The prognostic value of the SNPs was analysed using multiple logistic regression for all patients and histology-, stage-and treatment-specific subgroups. Hazard ratio estimates for PFS and OS were calculated using Cox regression methods.None of the investigated polymorphisms modified response significantly in the whole patient population.However, tumour stage IIIB variant allele carriers of MMP2 C-735T showed a significantly worse response. PFS was significantly prolonged in MMP1 G-1607GG variant allele carriers and OS in small cell lung cancer patients carrying the MMP12 A-82G variant allele.In conclusion, this study identified SNPs in MMP1, MMP2, MMP7 and MMP12 for further investigation as possible predictors of chemotherapy outcome in lung cancer patients.

show abstract

Section: Discussionsupporting

confidence: 92%

“…MMP3, MMP7 and MMP9, have also been reported to influence the Fas/FasL-mediated extrinsic, as well as the p53/PKC mediated intrinsic apoptotic pathway [6,7]. By cleavage of plasminogen and collagen XVIII, MMP12 is one of the most effective producers of the angiogenesis inhibitors angiostatin and endostatin [8].…”

mentioning

confidence: 99%

Single nucleotide polymorphisms in matrix metalloproteinase genes and lung cancer chemotherapy response and prognosis

Scherf

Dally²,

Müller³

et al. 2009

European Respiratory Journal

View full text Add to dashboard Cite

show abstract

“…Indeed, we found interactions between XRCC1:Arg399Gln and another DNA repair GSV ERCC5:His110Asp and an inflammatory gene sequence variant MMP3:À1612insA. Both ERCC5:His110Asp and MMP3:À1612insA sequence variants are known to be associated with head and neck cancer outcome (33,34). ERCC5:His110Asp is located at the Cterminal end of ERCC5 that is a conserved domain and is required for interactions with other interacting proteins in the incision complex of DNA repair pathways (35).…”

Section: Discussionmentioning

confidence: 85%

Validation of Genetic Sequence Variants as Prognostic Factors in Early-Stage Head and Neck Squamous Cell Cancer Survival

Azad

Bairati

Samson

et al. 2012

Clinical Cancer Research

View full text Add to dashboard Cite

Purpose: From the published literature, we identified 23 germ line sequence variants in 17 genes from hypothesis-generating studies that were associated with prognosis of head and neck cancer, including sequence variants of DNA repair (ERCC1, ERCC4, ERCC5, MSH2, XPA, ERCC2, XRCC1, XRCC3), DNA methylation (DNMT3B), cell cycle and proliferation (CCND1, TP53), xenobiotic metabolism (GSTM1, GSTT1, CYP2D6), metastatic -potential (MMP3), immunologic (CTLA4), and growth factor pathways (FGFR4). The purpose of this study was to validate the role of these 23 sequence variants for overall (OS) and disease-free survival (DFS) in a large, comprehensive, well-annotated data set of patients with head and neck cancer.Experimental Design: We genotyped these sequence variants in 531 patients with stage I and II radiation-treated head and neck cancer (originally recruited for an alpha-tocopherol/beta-carotene placebo-controlled secondary prevention study), and analyzed using Cox proportional hazards models, stratified by treatment arm, adjusting for clinical prognostic factors.Results: Two OS associations were statistically significant for each variant allele when compared with the wild-type: CTLA4:A49G [rs231775; adjusted HR (aHR), 1.32 (1.1-1.6); P ¼ 0.01] and XRCC1:Arg339Gln [rs25487; aHR, 1.28 (1.05-1.57); P ¼ 0.02]. Both of these sequence variants had significant results in the opposite direction as prior published literature. Two DFS associations were of borderline significance in the same direction as prior literature: ERCC2:Lys751Gln [rs13181; aHR, 0.80 (0.6-1.0); P ¼ 0.05] and TP53: Arg72Pro [rs1042522; aHR, 1.28 (1.0-1.6); P ¼ 0.03], comparing number of variant alleles with reference of zero variants.Conclusions: None of the prognostic sequence variants previously published was validated for OS in our patients with early-stage radiation-treated head and neck cancer, though rs1381and rs1042522 had borderline significant association with DFS.

show abstract

“…This study was performed on patients with histologically proven HNSCC managed at the Laennec Hospital (Paris, France) who had been prospectively included in a previous study in which response to neoadjuvant chemotherapy was assessed (Blons et al, 2004). The inclusion criteria retained were the following: no previous history of cancer, no multiple tumour locations, no contraindication for a 5FU-or cisplatin-based chemotherapy and indication for neoadjuvant chemotherapy prior to surgery or radiotherapy.…”

Section: Patientsmentioning

confidence: 99%

Clinicopathological significance of mitochondrial D-Loop mutations in head and neck carcinoma

et al. 2006

View full text Add to dashboard Cite

Mitochondrial DNA mutations have been reported in several types of tumours, including head and neck squamous cell carcinoma (HNSCC). The noncoding region of the Displacement-Loop (D-Loop) has emerged as a mutational hotspot and we recently found that they were associated with prognosis and response to 5 fluorouracil (5FU) in colon cancers. In order to evaluate the frequence of D-Loop mutations in a large series of HNSCC and establish correlations with clinicopathologic parameters, we sequenced the D-Loop of 109 HNSCC before a treatment by neoadjuvant 5FU-cisplatin-based chemotherapy and surgery. Then, we correlated these mutations with prognosis and response to chemotherapy. A D-Loop mutation was identified in 21% of the tumors, the majority of them were located in a C-tract (D310). The prevalence of D310 mutations increased significantly with the number of cytosines in the matched normal tissue sequence (P ¼ 0.02). Hypopharyngeal cancer was significantly more frequent (P ¼ 0.03) and tobacco consumption more important (P ¼ 0.01) in the group of patients with D-Loop mutation. The presence of D-Loop mutation was not associated with prognosis or with response to neoadjuvant chemotherapy. These results suggest that D-Loop mutations should be considered as a cancer biomarker that may be useful for the early detection of HNSCC in individuals at risk of this cancer.

show abstract

Matrix Metalloproteinase 3 Polymorphism

Cited by 33 publications

References 27 publications

Single nucleotide polymorphisms in matrix metalloproteinase genes and lung cancer chemotherapy response and prognosis

Single nucleotide polymorphisms in matrix metalloproteinase genes and lung cancer chemotherapy response and prognosis

Validation of Genetic Sequence Variants as Prognostic Factors in Early-Stage Head and Neck Squamous Cell Cancer Survival

Clinicopathological significance of mitochondrial D-Loop mutations in head and neck carcinoma

Contact Info

Product

Resources

About